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Abstract: Background: Cardiopulmonary exercise testing with ventilatory expired gas analysis (CPET) has proven to be 
a valuable tool for assessing patients with chronic heart failure (CHF). The maximal oxygen uptake (peak V02) is used in 
risk stratification of patients with CHF. The minute ventilation-carbon dioxide production relationship (VE/VCO2 slope) 
has recently demonstrated prognostic significance in patients with CHF.  
Methods: Between January 2006 and December 2007 we performed CPET in 184 pts (146 M, 38 F, mean age 59.8 + 12.9 
years), with stable CHF (96 coronary artery disease, 88 dilated cardiomyopathy), in NYHA functional class II (n.107) - III 
(n.77), with left ventricular ejection fraction (LVEF) < 45%,. The ability of peak VO2 and VE/VCO2 slope to predict car-
diac related mortality and cardiac related hospitalization within 12 months after evaluation was examined. 
Results: Peak VO2 and VE/VCO2 slope were demonstrated with univariate Cox regression analysis both to be significant 
predictor of cardiac-related mortality and hospitalization (p < 0.0001, respectively). Non survivors had a lower peak VO2 
(10.49 + 1.70 ml/kg/min vs. 14.41 + 3.02 ml/kg/min, p < 0.0001), and steeper Ve/VCO2 slope (41.80 + 8.07 vs. 29.84 + 
6.47, p < 0.0001) than survivors. Multivariate survival analysis revealed that VE/VCO2 slope added additional value to 
VO2 peak as an independent prognostic factor (2: 56.48, relative risk: 1.08, 95% CI: 1.03 – 1.13, p = 0.001). The results 
from Kaplan-Meier analysis revealed a 1-year cardiac-related mortality of 75% in patients with VE/VCO2 slope > 35.6 
and 25% in those with VE/VCO2 slope < 35.6 (log rank 2: 67.03, p < 0.0001) and 66% in patients with peak VO2 < 12.2 
ml/kg/min and 34% in those with peak VO2 > 12.2 ml/kg/min (log rank 2: 50.98, p < 0.0001). One-year cardiac-related 
hospitalization was 77% in patients with VE/VCO2 slope > 32.5 and 23% in those with VE/VCO2 slope < 32.5 (log rank 
2: 133.80, p < 0.0001) and 63% in patients with peak VO2 < 12.3 ml/kg/min and 37% in those with peak VO2 > 12.3 
ml/kg/min (log rank 2: 72.86, p < 0.0001). The VE/VCO2 slope was demonstrated with receiver operating characteristic 
curve analysis to be equivalent to peak VO2 in predicting cardiac-related mortality (0.89 vs. 0.89). Although area under 
the receiver operating characteristic curve for the VE/VCO2 slope was greater than peak VO2 in predicting cardiac-
related hospitalization (0.88 vs 0.82), the difference was no statistically significant (p = 0.13). 
Conclusion: These results add to the present body of knowledge supporting the use of CPET in CHF patients. The 
VE/VCO2 slope, as an index of ventilatory response to exercise, is an excellent prognostic parameter and improves the 
risk stratification of CHF patients. It is easier to obtain than parameters of maximal exercise capacity and is of equivalent 
prognostic importance than peak VO2. 
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INTRODUCTION 
  Despite recent advances in pharmacological treatment of 
patients with chronic heart failure (CHF), including ACE 128    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Sarullo et al. 
inhibitors and -blockers [1-4], mortality rates in patients 
with severe CHF remain high. The identification of patients 
at highest risk for early death from heart failure is of special 
importance. Peak oxygen consumption (peak VO2) has con-
sistently demonstrated prognostic significance [5-8] and is 
the most frequently analyzed cardiopulmonary exercise test 
parameter [9, 10]. In conjunction with other classic risk fac-
tors such as left ventricular ejection fraction (LVEF), New 
York Heart Association (NYHA) class IV symptoms, and 
neurohormonal markers, peak VO2 is used to assess survival 
and the need for heart transplantation [11-14].  
  Peak VO2 might be underestimated because of reduced 
patient motivation as well as premature termination of exer-
cise by the examiner. Recently, other ventilatory expired gas 
parameters obtained during exercise testing have demon-
strated prognostic value. The relationship between minute 
ventilation and carbon dioxide production (VE/VCO2 slope) 
is one such cardiopulmonary exercise test parameter that 
appears to have clinical value [8, 14-20]. It can be derived 
from submaximal exercise testing and is independent of pa-
tient motivation. The purpose of this study was to compare 
peak VO2 and the VE/VCO2 slope for predicting cardiac 
related mortality and cardiac related hospitalization (12-
months) in patients with CHF. 
METHODS 
Patients 
  Initially, 215 consecutive patients with chronic heart fail-
ure in stable condition were recruited. However, after the 
screening visit at baseline, 31 patients decided not to partici-
pate. Thus, 184 patients (mean age, 59.8 + 12.9 years) were 
studied between January 2006 and December 2007. All pa-
tients were clinically stable on standard medical therapy (an-
giotensin-converting enzyme inhibitors, beta-blockers, ni-
trates, diuretics, amiodarone and digoxin as necessary) in the 
3 months before the study. Criteria for eligibility were 
documented clinical signs and symptoms of heart failure, left 
ventricular ejection fraction < 45%, NYHA class II to III, 
and sinus rhythm. Clinical characteristics of the patients are 
summarized in Table 1. The cause of heart failure was 
ischemic (52.2%) and hypertensive cardiomyopathy or idio-
pathic dilated cardiomyopathy (47.8%). Mitral insufficiency 
was present in 83 patients and was mild in all. Exclusion 
criteria were unstable angina, recent acute myocardial infarc-
tion, decompensated congestive heart failure, hemodynami-
cally significant valvular heart disease, poorly controlled 
cardiac arrhythmias, significant chronic pulmonary illness, 
renal insufficiency (serum creatinine > 2.5 mg/dL), exercise 
testing limited by angina or leg claudication, abnormal blood 
Table 1.  Clinical Characteristics of the Study Population 
 
Patients (no.) 
All Patients 
184 
Survivors 
156 
Non Survivors 
28 
p 
Age (y)  59.8 + 12.9  58.6 + 12.9  67.8 + 9.1  0.002 
Sex, male, n (%)  146 (79.3)  126 (80.7)  20 (71.4)  n.s. 
Weight (Kg)  76.3 + 11.7  77.2 + 10.8  77.1 + 11.2  n.s. 
Height (cm)  169 + 6.7  170 + 7.1  169 + 7.2  n.s. 
Body Mass Index (kg/m2)  27.4 + 4.1  26.9 + 5.0  27.2 + 4.6  n.s. 
NYHA – FC II/III  2.4 + 0.5  2.3 + 0.5  2.8 + 0.4  < 0.0001 
LVEF (%)  35.40 + 7.38  36.45 + 7.13  30.29 + 6.62  < 0.0001 
  CHF cause (%) 
Ischemic  96 (52.2)  81 (51.9)  15 (53.6)  n.s. 
Non-ischemic  88 (47.8)  75 (48.1)  13 (46.4)  n.s. 
  Medications (%) 
-blockers  116 (63.0)  100 (64.1)  16 (57.1)  n.s. 
Amiodarone  61 (33.2)  48 (30.7)  13 (46.4)  n.s. 
Nitrates   86 (46.7)  74 (47.4)  12 (42.8)  n.s. 
Diuretics  178 (96.7)   150 (96.1)  28 (100)  n.s. 
ACE- I  153 (83.1)   131 (83.9)  22 (78.6)  n.s. 
Digoxin  65 (35.3)  52 (33.3)  13 (46.4)  n.s. 
Aspirin  96 (52.2)  81 (51.3)  15 (53.6)  n.s. 
Anticoagulants  60 (32.6)  50 (32)  10 (35.7)  n.s. 
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pressure response to exercise testing (systolic blood pressure 
during exercise > 250 mmHg or diastolic blood pressure > 
120 mmHg, systolic blood pressure response decrease > 20 
mmHg after a normal increase or decrease below the resting 
level), and neurological or orthopedic limitations.  
CARDIOPULMONARY EXERCISE TESTING 
  All patients performed symptom-limited incremental 
cycle ergometer exercise testing with electrocardiographic 
monitoring. Patients pedalled in the upright position on an 
electronically braked cycle ergometer (Lode Corival, Gron-
inger – The Netherlands) at a constant rate of 60 rpm. The 
work load started at 20 watts (W) for 3 minutes (warming-
up) and increased by 1 W every 5 seconds (ramp protocol). 
Blood pressure was measured by auscultation every other 
work load. The 12-lead electrocardiogram was recorded dur-
ing the final 30 seconds of every other work load and at the 
peak exercise. Heart rate was determined from the electro-
cardiographic recording. Symptoms were assessed by means 
of the 10-point Borg scale rating. Calibration of volumes and 
gases (O2 and CO2) was carefully performed before each 
test. The ventilatory threshold was measured by the V-slope 
method [21]. Peak oxygen uptake was measured with com-
mercially available metabolic carts (Sensor Medics model 
Vmax, Yorba Linda, CA- USA) and defined as the highest 
oxygen consumption during the last 30 seconds of exercise. 
VE/VCO2 slope was calculated with the slope calculation 
option of the spreadsheet software package. 
END POINT 
  Subjects were observed for cardiac related mortality and 
hospitalization 1–year after exercise testing. Medical chart 
review and telephone interviews were used to contact pa-
tients or their relatives. In the follow-up interviews, patients 
were asked about re-admission to the hospital and any other 
cardiac events. Events were defined as acute myocardial 
infarction (AMI) followed by cardiac arrest or decompensate 
heart failure (HF) requiring the use of an intravenous 
inotropic agent and loop diuretics. Cardiac-related mortality 
was defined as death directly resulting from failure of the 
cardiac system. Cardiac-related hospitalization was defined 
as a hospital admission directly resulting from cardiac dys-
function requiring inpatient care to correct. The most com-
mon causes of mortality, as per discharge diagnosis, were 
cardiac arrest, myocardial infarction, and end-stage HF. The 
most common causes of hospitalization were decompensated 
HF and coronary artery disease. Patients in whom mortality 
or hospitalization were of non cardiac etiology were treated 
as censored cases. 
STATISTICAL ANALYSIS 
  Continuous variables are expressed as the mean + stan-
dard deviation (SD). Discrete variables are shown as abso-
lute value and/or percentages + SD. Pearson’s correlation 
coefficient was used to evaluate the bivariate relationships. 
Analysis of variance with the Bonferroni correction of the 
post hoc test of significance was used for the statistical 
evaluation of the differences between groups. The chi-
squared test was used for evaluation of categorized variables. 
Univariate Cox regression analysis was used to determine 
the ability of peak VO2 and VE/VCO2 slope to predict 1-
year cardiac related mortality, and 1-year cardiac related 
hospitalization.  
  Multivariate Cox regression analysis (forward stepwise 
method) with peak VO2 and VE/VCO2 slope, was used to 
assess the combined effect of these variables in predicting 
the aforementioned end points. Entry and removal P value 
for the multivariate analyses were set at 0.05 and 0.10, re-
spectively. 
  Receiver operator characteristic (ROC) analysis was   
carried out to determine the cut-off value of the parameters 
used in the Cox regression analysis. Survival curves were 
constructed by the Kaplan Meier method and were compared 
with the log-rank test. 
  Differences were considered significant at a P-value < 
0.05. All analyses were performed using the MedCalc Soft-
ware Version 10.4.5. 
RESULTS 
Baseline Characteristics 
  Descriptive characteristics of the study population a pre-
sented in Table 1. Ischemic cardiomyopathy was the pre-
dominant underlying cause of CHF (96 patients, 52.2%). 
LVEF was reduced to 35.4 + 7.3%. All patients had symp-
tomatic heart failure, with a mean NYHA class of 2.4 + 0.5. 
The medical treatment included diuretics in 96.7%, ACE 
inhibitors in 83.1%, -blockers (carvedilol, bisoprolol) in 
63%, nitrates in 46.7%, digitalis in 35.3%, amiodarone in 
33.2%, aspirin in 52.2% and anticoagulants in 32.6% of the 
patients. Twelve patients (6.5%) had pacemakers and an-
other 19 patients (10.3%) had an implanted cardioverter-
defibrillator (ICD). 
FOLLOW-UP SURVIVAL 
  None of patients were lost to follow-up. During the me-
dian follow-up of 10 + 3 months, 28 patients died (non-
survivors). Two patients with an ICD had ventricular fibrilla-
tion, detected and successful treated by the ICD. Fourteen 
patients (50%) died within the first 6 months of follow-up. 
None of the patients underwent heart transplantation. The 
clinical characteristics of the survivors and non-survivors are 
presented in Table 1. The non-survivor were similar to the 
survivors in sex, body mass index, and in the cause of CHF 
but were older, more symptomatic (high NYHA class), and 
had a lower LVEF (Table 1). 
CARDIOPULMONARY EXERCISE TESTING 
  Exercise was stopped for fatigue or exhaustion in 128 
patients (69.6%), angina in 14 patients (7.6%) and dyspnea 
in 42 patients (22.8%). All measurements of exercise capac-
ity with the exception of O2-pulse and breathing reserve 
were lower in non-survivors than survivors. There was no 
difference in heart rate at rest or at maximal exercise be-
tween both groups. The maximal work load was lower in 
non-survivors (Table 2). 
CARDIOPULMONARY PREDICTORS OF MORTAL-
ITY AND HOSPITALIZATION 
  There were 28 cardiac-related deaths (10 suddenly and 
18 from end-stage CHF) and 66 cardiac-related hospitaliza-
tion within 1-year after exercise testing. There were no addi-130    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Sarullo et al. 
tional non-cardiac deaths during the follow up period. With 
univariate Cox regression analysis, both peak VO2 and 
VE/VCO2 slope were revealed to be significant predictor of 
all 2 outcomes assessed (Table 3). This was confirmed by 
the stepwise multivariate Cox proportional hazard analysis, 
where these two variables were considered independent pre-
dictors (Table 4). In addition, the multivariate analysis 
showed that only the NYHA functional class was independ-
ent predictor of mortality (p<0.0001). Cut-off values were 
determined by ROC curve analysis. The cut-off value for 
VE/VCO2 slope in predicting 1-year cardiac related mortal-
ity was 35.6 (89.3% sensibility, 84.7% specificity, AUC = 
0.891 + 0.041, p = 0.0001), and 32.5 (78.8% sensibility, 
94.1% specificity, AUC = 0.888 + 0.028, p = 0.0001) for 1-
year cardiac related hospitalization. For VO2 peak cut-off 
value in predicting 1-year cardiac related mortality was 12.2 
(89.3% sensibility, 79.6% specificity, AUC = 0.892 + 0.025, 
p = 0.0001), and 12.3 (66.7% sensibility, 86.6% specificity, 
AUC = 0.827 + 0.030, p = 0.0001) for 1-year cardiac related 
hospitalization (Table 5). The results from Kaplan-Meir 
analysis revealed a 1-year cardiac-related mortality of 66% 
in patients with peak VO2 < 12.2 ml/kg/min and 34% in 
those with peak VO2 > 12.2 ml/kg/min (log rank 2: 50.98, p 
<0.0001) (Fig. 1) and 75% in patients with VE/VCO2 slope 
> 35.6 and 25% in those with VE/VCO2 slope < 35.6 (log 
rank 2: 67.03, p < 0.0001) (Fig. 2). One-year cardiac-related 
hospitalization was 63% in patients with peak VO2 < 12.3 
ml/kg/min and 37% in those with peak VO2 > 12.3 
ml/kg/min (log rank 2: 72.86, p < 0.0001) (Fig. 3) and 77% 
in patients with VE/VCO2 slope > 32.5 and 23% in those 
with VE/VCO2 slope < 32.5 (log rank 2: 133.80, p < 
0.0001) (Fig. 4).  
DISCUSSION 
  Beginning in the mid-1990s, consensus guidelines rec-
ommended the application of the CPET to supplement other 
clinical data in the management of patients with CHF. How-
ever, these guidelines limited their recommendations to the 
application of the peak VO2 achieved in the context of se-
lecting patients for transplantation. Peak VO2 has been the 
most widely used parameter to predict survival and re-
hospitalization in patients with CHF [22]. The main disad-
vantage of peak VO2 is the need for maximal exercise, 
which may be difficult to achieve, particularly in CHF pa-
tients, whose daily activity levels are far below the effort 
required by the test. In addition, VO2 peak may be underes-
Table 2.  Cardiopulmonary Exercise Measurements in the Overall Patients Population and in the Survivors and Non-Survivors* 
Variables All  Patients 
(n.184) 
Survivors 
(n.156) 
Non-Survivors 
(n.28) 
p 
Heart rate at rest (bpm)  84 + 13  82 + 12  86 + 14  n.s. 
Heart rate at peak (bmp)  121 + 21  119 + 20  126 + 22  n.s. 
Maximal work load (watt)  98 + 48  106 + 51  76 + 49  0.004 
VO2 peak (ml/kg/min)  13.82 + 3.19  14.41 + 3.02  10.49 + 1.7  < 0.0001 
VO2-AT (ml/k/min)   12.50 + 3.0  13.04 + 2.87  9.50 + 1.71  < 0.0001 
VE/VCO2 slope   31.66 + 7.98  29.84 + 6.47  41.80 + 8.07  < 0.0001 
VO2/HR (ml/beat)  9.44 + 2.65  9.68 + 2.63  8.72 + 2.36  n.s. 
Breathing reserves (%)  41.7 + 17.2  39.8 + 16.9  45.2 + 16.6  n.s. 
* The data are given as mean + SD. 
 
Table 3.  Univariate Cox Regression Results for Peak VO2 and VE/VCO2 Slope 
Variables  Event  Number of Events  X 2  p  95% CI 
VO2 peak  Cardiac mortality (1 y) 
Cardiac hospitalization (1 y) 
28 
66 
42.09 
54.98 
<0.0001 
<0.0001 
5.44 – 37.12 
3.99 - 10.89 
VE/VCO2 slope  Cardiac mortality (1 y) 
Cardiac hospitalization (1 y) 
28 
66 
44.48 
70.41 
<0.0001 
<0.0001 
1.09 – 1.17 
1.08 – 1.13 
 
Table 4. Multivariate Cox regression survival analysis 
Variables Interval  X 2  p  Relative Risk  95% Confidence 
VO2 peak  57.39   0.002  5.69  1.87 – 17.28 
VE/VCO2 slope  56.48  0.001  1.08  1.03 – 1.13 Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure  The Open Cardiovascular Medicine Journal, 2010, Volume 4    131 
timated because of low patient motivation or because of pre-
mature termination of the test by the physician. A third 
potential limitation is the contribution peripheral metabolism 
has on VO2 peak. This contribution is made apparent with 
investigation demonstrating that high values for VO2 peak 
are paralleled by superior skeletal muscle metabolic capacity 
[23]. The prognostic role of VO2 peak is clear from these 
observations; however, an actual cut-off for decision proba-
bly does not exist. Although VO2 peak value < 14 ml/kg/min 
is recommended for selecting potential candidates for heart 
transplantation, since these patients had the worst prognosis 
[5], there is no distinct threshold in the 10-18 ml/kg/min 
range [6] which corresponds to an intermediate exercise   
capacity, the level reached by the majority of patients with 
CHF. We confirmed that a peak VO2 < 12.2 ml/kg/min sig-
nifies a worse prognosis than a higher peak VO2 in our 
population of patients with CHF. In fact, patients with a low 
VO2 peak (< 12.2 ml/kg/min) had a 1-year cardiac mortality 
of 66% and a 1-year cardiac hospitalization of 63%, while 
those exceeding this threshold had only 34% and 37% re-
spectively. 
Table 5.  ROC Curve Analysis for the Peak VO2 and VE/VCO2 Slope Classifications 
Variables   Event  Number of 
Events 
Area Under the  
ROC Curve 
p Sensibility  %  Specificity  % 
VO2 peak  Cardiac mortality (1 y) 
Cardiac hospitalization (1 y) 
28 
66 
0.892 
0.827 
0.0001 
0.0001 
89.3 
66.7 
79.6 
86.6 
VE/VCO2 slope  Cardiac mortality (1 y) 
Cardiac hospitalization (1 y) 
28 
66 
0.891 
0.888 
0.0001 
0.0001 
89.3 
78.8 
84.7 
94.1 
 
 
 
 
 
 
 
 
Fig. (1). Kaplan Meier analysis for 1-year cardiac-related mortality with VO2 peak threshold of 12.2. 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Kaplan Meier analysis for 1-year cardiac-related mortality with VE/VCO2 slope threshold of 35.6. 
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  After the ventilator response to exercise was confirmed 
as a significant prognostic marker [14-20], the VE/VCO2 
slope seemed to be a strong candidate as a risk predictor in 
CHF even in those patients with intermediate exercise intol-
erance [16]. In our study, the VE/VCO2 slope manifests 
considerable prognostic value. Patients with VE/VCO2 slope 
> 35.6 ml/kg/min revealed a 1-year cardiac-related mortality 
of 75% and a 1-year cardiac hospitalization of 77%, while 
those below this threshold had only 25% and 23% respec-
tively. The ROC curve for VE/VcO2 slope to predict 1 year 
survival is similar in shape and area to that for peak VO2, 
implying equivalent prognostic power. The final result of our 
study, in agreement with other authors [14-20], was that 
VO2 peak and VE/VCO2 slope can be calculated to provide 
a risk surface for evaluating prognosis in CHF. There are 
several possible reasons why progressively higher VE/VCO2 
slope might predict higher mortality and hospitalization 
across a range of peak VO2 value. Firstly, steepening of the 
VE/VCO2 slope is associated with reduced peak cardiac 
output and restrictive pattern of pulmonary dysfunction, an 
impairment mainly attributed to subclinical alveolar and in-
terstitial pulmonary oedema [19]. Secondly, it may indicate 
enhanced ventilator reflex sensibility [24]. A third considera-
tion is that the VE/VCO2 slope is computed using far more 
data than is peak VO2: it is accordingly less susceptible [25] 
to vagaries of CHF such as irregular breathing and early sub-
jective fatigue which may sometimes interfere with determi-
nation of VO2 peak. 
  We chose to limit the tracking period to 1 year in the 
present investigation, since previous work by other group 
has demonstrated that the prognostic power of CPET vari-
ables begins to diminish over time [26]. Use of VO2 peak 
and VE/VCO2 slope to assess risk for cardiac-related mortal-
ity or cardiac-related hospitalization for one year period ap-
pears appropriate. Assessment of the risk using the VO2 
peak and VE/VCO2 slope for longer tracking periods will 
result in an unacceptable decline in prognostic specificity. 
Numerous interventions, such as prescription of beta-
blocking agents [3, 27] and aerobic exercise training [28], 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Kaplan Meier analysis for 1-year cardiac-related hospitalization with VO2 peak threshold of 12.2. 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Kaplan Meier analysis for 1-year cardiac-related hospitalization with VE/VCO2 slope peak threshold of 35,6. 
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have been shown to reduce cardiac-related hospitalization 
rate in patients with CHF. Utilization of the VO2 peak and 
VE/VCO2 slope may be used to prompt clinicians to assess 
the current management of individuals deemed to be at high 
risk for hospitalization and alter care when appropriate.  
LIMITATIONS OF THE STUDY 
  Although the large numbers of cardiac event were re-
corded during the tracking period, the relatively small sam-
ple size of the present study is a limitation. The fact that 
none of the subjects were NYHA class IV may also limit 
application of our findings to group with more severe CHF. 
Lastly, a number of previous studies have examined the im-
pact beta-blockade on the prognostic characteristics of CPET 
variables, primarily peak VO2 [29, 30]. These studies have 
generally found that peak VO2 is still predictive of outcomes 
in patients receiving beta-blocking agent. Six-three percent 
of the subjects in the present study were prescribed a beta-
blockers. Again the small overall sample size of the present 
study limited the ability to examine the influence of beta-
blockade on the prognostic value of VE/VCO2 slope. Future 
research should investigate the impact of beta-blocker ther-
apy on the prognostic value of VE/VCO2 slope as well as 
other CPET variables. 
CONCLUSION 
  These results add to the present body of knowledge sup-
porting the use of CPET in CHF patients. The VE/VCO2 
slope, as an index of ventilatory response to exercise, is an 
excellent prognostic parameter and improves the risk stratifi-
cation of CHF patients. It is easier to obtain than parameters 
of maximal exercise capacity and have similar prognostic 
importance than peak VO2. 
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